Literature DB >> 15892297

The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas.

Akiyoshi Ogino1, Atsuo Yoshino, Yoichi Katayama, Takao Watanabe, Takashi Ota, Chiaki Komine, Takakazu Yokoyama, Takao Fukushima.   

Abstract

Pituitary adenomas are common benign intracranial neoplasms. However, their tumorigenesis is not yet clearly defined. Inactivation of genes involved in the negative cell-cycle regulatory p15(INK4b) - p16(INK4a) -cyclin D/CDK4-RB1-mediated pathway (RB1 pathway) is one of the most common and important mechanisms in the growth advantage of tumor cells. Recently, much attention has been focused on the importance of alternative mechanisms of gene inactivation, particularly promoter hypermethylation in the transcriptional silencing of such tumor-suppressor genes. Based on the rare occurrence of inactivation by gene mutations and deletions of the RB1 pathway in pituitary adenomas, we investigated the deregulation of the RB1 pathway in 42 sporadic human pituitary adenomas, especially focusing on the methylation status of this pathway as determined by a methylation-specific polymerase chain reaction assay. Homozygous deletion of the p15(INK4b) or p16(INK4a) gene was detected in one adenoma each. Amplification of the CDK4 gene was not apparent in any of the pituitary adenomas presently examined. Promoter hypermethylation of the p15(INK4b), p16(INK4a), and RB1 genes was detected in 15 (35.7%), 30 (71.4%), and 12 (28.6%) of the adenomas, respectively. Promoter hypermethylation of the p15(INK4b) gene coincided with p16(INK4a) alteration and/or RB1 methylation, whereas p16(INK4a) and RB1 methylations tended to be mutually exclusive (p = 0.019). Thus, the vast majority of the adenomas (38 of 42, 90.5%) displayed alterations of the RB1 pathway. None of the clinicopathologic features, including the proliferation cell index, was significantly correlated with any particular methylation status. Our results suggest that inactivation of the RB1 pathway may play a causal role in pituitary tumorigenesis, with hypermethylation of the p16(INK4a) gene being the most common deregulation, and further provide evidence that RB1 and p16(INK4a) methylations tend to be mutually exclusive but occasionally coincide with p15(INK4b) methylation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15892297     DOI: 10.1093/jnen/64.5.398

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  22 in total

1.  A pilot genome-scale profiling of DNA methylation in sporadic pituitary macroadenomas: association with tumor invasion and histopathological subtype.

Authors:  Chao Ling; Matthew Pease; Lingling Shi; Vasu Punj; Mark S Shiroishi; Deborah Commins; Daniel J Weisenberger; Kai Wang; Gabriel Zada
Journal:  PLoS One       Date:  2014-04-29       Impact factor: 3.240

2.  Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas.

Authors:  Henriett Butz; Kinga Németh; Dóra Czenke; István Likó; Sándor Czirják; Vladimir Zivkovic; Kornélia Baghy; Márta Korbonits; Ilona Kovalszky; Péter Igaz; Károly Rácz; Attila Patócs
Journal:  Pathol Oncol Res       Date:  2016-12-21       Impact factor: 3.201

3.  Oncogene-Induced Senescence in Pituitary Adenomas--an Immunohistochemical Study.

Authors:  Emilija Manojlovic-Gacic; Milica Skender-Gazibara; Vera Popovic; Ivan Soldatovic; Novica Boricic; Savo Raicevic; Sandra Pekic; Mirjana Doknic; Dragana Miljic; Irina Alafuzoff; Fredrik Pontén; Olivera Casar-Borota
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

Review 4.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

5.  Association between p16(CDKN2A) C540G polymorphism and tumor behavior in prolactinoma: A single-center study.

Authors:  Soner Cander; Mutlu Karkucak; Ozen Oz Gul; Sebnem Ozemri Sag; Tahsin Yakut; Canan Ersoy; Ercan Tuncel; Erdinc Erturk
Journal:  Biomed Rep       Date:  2014-05-19

Review 6.  Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

7.  Expression of p16(INK4A) gene in human pituitary tumours.

Authors:  Gloria Machiavelli; Javier Cotignola; Karina Danilowicz; Carolina Carbonara; Andrea Paes de Lima; Armando Basso; Oscar Domingo Bruno; Irene Szijan
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 8.  Pituitary adenomas: historical perspective, surgical management and future directions.

Authors:  Debebe Theodros; Mira Patel; Jacob Ruzevick; Michael Lim; Chetan Bettegowda
Journal:  CNS Oncol       Date:  2015-10-26

9.  Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas.

Authors:  Atsuo Yoshino; Yoichi Katayama; Akiyoshi Ogino; Takao Watanabe; Kazunari Yachi; Takashi Ohta; Chiaki Komine; Takakazu Yokoyama; Takao Fukushima
Journal:  J Neurooncol       Date:  2007-01-11       Impact factor: 4.506

10.  GFAP-Cre-mediated transgenic activation of Bmi1 results in pituitary tumors.

Authors:  Bart A Westerman; Marleen Blom; Ellen Tanger; Martin van der Valk; Ji-Ying Song; Marije van Santen; Jules Gadiot; Paulien Cornelissen-Steijger; John Zevenhoven; Haydn M Prosser; Anthony Uren; Eleonora Aronica; Maarten van Lohuizen
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.